Medical experts explore recent therapies in the treatment of dry eye disease.
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Haumschild asks about promising emerging dry eye disease (DED) therapies targeting symptoms and causes. Kabiri cites the recent approval of perfluorohexyloctane, taken 4 times daily, as an effective, safe, accessible treatment specifically addressing the predominant evaporative DED component.
Parekh notes the recent first-in-class evaporative DED treatment approval has generated great enthusiasm after decades of unmet need in this area, joining other emerging options like a new medication for a DED-exacerbating mite, a topical steroid specifically for intermittent DED flares, and pipeline immunomodulators with alternate anti-inflammatory mechanisms. He notes DED’s rising prominence is attracting investments into therapeutic innovation. Kabiri adds that the approved evaporative DED medication has a simple educational message around mechanism. This avoids intimidation barriers that can impede provider adoption and patient compliance relative to emerging therapies.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More